We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




New Risk Variants Identified for Restless Legs Syndrome

By LabMedica International staff writers
Posted on 24 Oct 2017
As many as one in ten people of European ancestry is affected by restless legs syndrome, in which sufferers feel an overwhelming urge to move, often in conjunction with unpleasant sensations, usually in the legs.

Rest and inactivity provoke the symptoms, whereas movement can lead to temporary relief. More...
The condition is chronic and can get progressively worse, with long-lasting effects on patients' mental and physical health. People with restless legs syndrome have substantially impaired sleep, reduced overall quality of life, and increased risk of depression, anxiety disorders, hypertension, and, possibly, cardiovascular disease.

An international team of scientists led by those at German Research Centre for Environmental Health (Neuherberg, Germany) have compared the genetic data from 15,126 patients with 95, 725 controls, and identified a further 13 genetic risk variants. The findings were then replicated in a sample of 31,000 patients and 287,000 controls. The team collected diagnosis data collected from 2003 to 2017, in face-to-face interviews or via questionnaires, and involving cases and controls of European ancestry.

The investigators performed a genome-wide association study (GWAS) and all European samples were genotyped on the Affymetrix Axiom CEU array and UK Samples were genotyped on the Affymetrix UK Biobank Axiom array. They identified common variants by fixed-effect inverse-variance meta-analysis. Significant genome-wide signals were tested for replication in an independent GWAS of 30,770 cases and 286,913 controls, followed by a joint analysis of the discovery and replication stages. They did gene annotation, pathway, and gene-set-enrichment analyses and studied the genetic correlations between restless legs syndrome and traits of interest.

The scientists identified and replicated 13 new risk loci for restless legs syndrome and confirmed the previously identified six risk loci. Meis Homeobox 1 (MEIS1) was confirmed as the strongest genetic risk factor for restless legs syndrome (odds ratio 1.92). Gene prioritization, enrichment, and genetic correlation analyses showed that identified pathways were related to neurodevelopment and highlighted genes linked to axon guidance (associated with SEMA6D), synapse formation (NTNG1), and neuronal specification (HOXB cluster family and MYT1).

Steven Bell, PhD, a genetic epidemiologist and a senior co-author said, “Restless legs syndrome is surprisingly common, but despite this, we know little about what causes it and hence how to treat it. We already know that it has a strong genetic link, and this was something we wanted to explore in more detail.” The study was published on October 10, 2017, in the journal Lancet Neurology.

Related Links:
German Research Centre for Environmental Health


Gold Member
Automatic Hematology Analyzer
CF9600
Online QC Software
Acusera 24•7
Prefilled Tubes
Prefilled 5.0ml Tubes
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The approach supports myocardial infarction diagnosis in resource-limited settings by reducing delays between clinical suspicion and biochemical confirmation (Image Credit: Adobe Stock)

Portable Troponin Assay Brings Heart Attack Diagnosis Closer to Patients

Timely confirmation of myocardial infarction often depends on laboratory testing that may not be immediately available at the point of care. This gap between clinical suspicion and definitive evidence... Read more

Microbiology

view channel
Image: An innovative countywide program in Taiwan combines risk-based screening with decentralized community care to improve hepatitis C detection and treatment (Image Credit: iStock)

Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps

Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more

Pathology

view channel
Image: Through the PCCP, Proscia gains a more efficient pathway to expand Concentriq AP-Dx interoperability while maintaining regulatory oversight (Photo courtesy of Proscia)

FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis

Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.